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Concerted efforts to eliminate lymphatic filariasis worldwide have registered success; multiple rounds of mass
drug administration have led to the interruption of transmission in many previously endemic areas. However,
themanagement of patients with established clinical disease (e.g., lymphoedema, hydrocoele and acute derma-
tolymphangioadenitis) has not been addressed sufficiently. Two recent studies fromMalawi underscore the need
for accurate epidemiological and clinical data, and comprehensive morbidity assessments across various
domains of daily life. Addressing these issues will guide the implementation of programmes to improve access
to treatment and disability prevention for affected individuals in Malawi and beyond.
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Lymphatic filariasis (LF) is a mosquito-borne neglected tropical
disease (NTD), caused by the nematode parasites Wuchereria
bancrofti, Brugia malayi and B. timori.1 LF is a high-morbidity, low-
mortality NTD with an estimated global burden of 2.78 million
disability-adjusted life years (DALYs).2,3 Adult filariae cause severe
damage to the lymphatic system of infected people, which leads
to considerable long-term morbidity. As many as 36 million indi-
viduals suffer from LF-related lymphoedema, elephantiasis and
hydrocoele. Manyof them regularly experience painful, erysipelas-
like manifestations, commonly referred to as acute dermatolym-
phangioadenitis (ADLA). This condition is caused by secondary
bacterial infection and accounts for much LF-related morbidity.4
In 2000, the Global Programme to Eliminate Lymphatic Filariasis
(GPELF)was launchedwith the goal to eliminate LFas a public health
problem by 2020. GPELF is built on two major pillars: 1. mass drug
administration (MDA) and complementary measures (e.g., vector
control) to prevent clinical disease and interrupt LF transmission;
and 2. morbidity management facilitated by improved access to
health care for those suffering from LF-related morbidity.5 While
MDA has been implemented successfully in 60 of the 73
LF-endemic countries, data on the burden of LF-related morbidity
are scarce and appropriate programmes for clinical management
of LF in endemic countries are relatively few.6
Two studies published in the Transactions of the Royal Society of
Tropical Medicine and Hygiene in December 2014 illustrate
pervasive morbidity patterns of LF and practical challenges for
an accurate estimation of the LF burden in endemic settings.
Research conducted by Smith and colleagues7 in the catchment
area of a health centre in southernMalawi revealed thatmorbidity
data routinely collected by community drug distributors during
MDA programmes considerably underestimated the true number
of lymphoedema cases. Indeed, administration of a questionnaire
and subsequent clinical examination found 69 cases of lymphoe-
dema (32 lymphoedema cases per 10 000 population), while
community drug distributors reported slightly less than half (33
cases). Most of the patients (94%) had experienced ADLA at
least once, and half of them reported having suffered≥2 episodes
during the past 6 months. A complementary study by Martindale
et al.8 employed a semi-structured questionnaire to investigate the
LF-related health impact in the 69 individuals with lymphoedema.
For eight distinct domains of daily life (8D), such as mobility, pain
and social participation, each individual was assigned scores at
five different levels (5L) to evaluate the perceived health impact
of LF. This 8D/5L survey revealed that most patients with lymphoe-
dema (77%) experienced negative economic consequences, e.g.,
due to reduced ability to walk or capacity towork. This loss of prod-
uctivity was further pronounced during ADLA. Indeed, one-third of
the patients reported missing days of work during the past
6 months due to such ‘acute attacks’. Disease-related pain/
discomfort (65%) and anxiety/depression (45%) due to disfigured
# The Author 2015. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved.
For permissions, please e-mail: journals.permissions@oup.com.
CO
M
M
E
N
TA
R
Y
Trans R Soc Trop Med Hyg 2015; 109: 357–359
doi:10.1093/trstmh/trv022 Advance Access publication 15 March 2015
357
limbs or hydrocoele were also frequently mentioned and empha-
sise the multifaceted impact of LF on quality of life.
Many implications for LF programmes and research arise from
these two Malawian studies, and we would like to highlight two
observations that are likely to be relevant in other LF-endemic
countries. First, disease burden estimates depend on quality
assessment of prevalence and incidence. The number of
lymphoedema cases identified through a questionnaire and
confirmatory clinical examination was more than twice that
obtained through data routinely collected during MDA activities.
The insufficient case detection rate during routine activities in
the Malawian studies is particularly worrying because GPELF
uses similar approaches in other LF-endemic settings for the
rapid epidemiological assessment ofmorbidity and MDA coverage
rates. It follows that there is a need to carefully evaluate the case
detection strategies for LF in all endemic areas. As interruption of
LF transmission has been achieved in several countries and MDA
programmes are scaling down,more emphasis needs to be placed
on the second pillar of GPELF, i.e., morbidity management and
prevention of disability. WHO recently recommended that
national programme managers ‘assess the numbers of cases of
ADLA, lymphoedema and hydrocoele in all implementation
units’ as a first step to implement morbidity management strat-
egies.9 Knowing the numbers will enable public health pro-
grammes to identify the funds and human resources needed to
reach those affected, to ensure proper training of healthcare pro-
fessionals across affected communities and ultimately, to provide
access to treatment and relieve patient suffering. This is of para-
mount importance in all LF-endemic areas as the chronic seque-
lae of LF will continue to cause significant morbidity in the
post-transmission era. Clinical assessment is key to accurately
estimating the magnitude of such ‘post-transmission morbidity’.
Second, the perceived impact on various domains of patients’
lives underscores the difficulty of accurately assessing the true
burden that is attributable to LF and other chronic NTDs, or even
the nature of that burden. It follows that aggregated burden of
disease measures should be interpreted with caution. For
instance, the DALY figure cited at the beginning of our commen-
tary does not sufficiently consider manifestations of ADLA, the
social and economic impact of LF due to lost working productivity,
the devastating effects on mental health due to stigma and dis-
crimination10,11 or subtle morbidity that may not easily come to
clinical attention.12 To more accurately estimate the LF burden
and its implications for the daily life of affected individuals,
other tools such as questionnaires evaluating the health-related
quality of life (HRQoL) have been proposed.13 These patient-based
HRQoL assessments are often summarised in burden estimates
based on quality-adjusted life years (QALYs). However, QALYs
have been criticised for the high variability of self-rated health
effects across different countries and cultures that minimise
comparability.14
In conclusion, the studies by Smith et al.7 and Martindale
et al.8 provide a detailed account of the numbers and the many
faces of LF-related morbidity in southern Malawi, both of which
remain all too often hidden. It is likely that the issues highlighted
here are equally relevant for other LF-endemic areas, particularly
the need for clinical surveys to define the extent of ADLA, lym-
phoedema and hydrocoele. Quality epidemiological data from
different settings will shapemorbiditymanagement and disability
prevention programmes, so that the ’faces behind the
numbers’,15 i.e., the millions of patients suffering from the afore-
mentioned conditions, finally gain adequate access to basic
health care, necessary treatment and additional support. While
GPELF has succeeded in preventing an enormous number of
future LF cases, the programme’s overall success or failure will
equally be determined by the quality of clinical care that is pro-
vided to affected individuals suffering from LF-related morbid
sequelae. Future interdisciplinary research should therefore priori-
tise the question of how the needs of these patients can be more
accurately assessed and met. In this spirit, the two studies
reviewed here can be seen as a gentle reminder for any public
health intervention to consider the numbers and faces of the
targeted condition to most effectively help those in need.
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